(CercleFinance.com) – Pherecydes Pharma announces that it has obtained, for its anti-Staphylococcus aureus (S. aureus) phages, a Compassionate Access Authorization (AAC) from the ANSM, which will allow the company to generate the first turnover in its history.
The AAC status, introduced in July 2021, allows certain categories of patients in France in a situation of therapeutic impasse to benefit from drugs that have not yet received marketing authorization.
To date, Pherecydes Pharma has treated more than 50 patients on a compassionate basis. ‘These phages, administered by different routes, have demonstrated excellent tolerance, with no reported side effects’, underlines the specialist in precision phage therapy.